ESMO News

Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context

noreply@esmo.org — Fri, 22 May 2026 07:05:00 +00:00

Findings from the EXTEND study

EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib

noreply@esmo.org — Fri, 22 May 2026 07:05:00 +00:00

Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016

ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC

noreply@esmo.org — Thu, 21 May 2026 07:05:00 +00:00

Findings from the TOMBOLA study

FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma

noreply@esmo.org — Wed, 20 May 2026 07:05:00 +00:00

Evidence for safety and efficacy is based on the findings from the eNRGy study

Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC

noreply@esmo.org — Tue, 19 May 2026 07:05:00 +00:00

Findings from the PLANeT study

ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly

noreply@esmo.org — Mon, 18 May 2026 13:05:00 +00:00

As a ‘Non-State actor in official relations with World Health Organization (WHO)’, ESMO will deliver statements at the 79^th World Health Assembly (WHA79) in Geneva, 18.-23. May 2026.

Additional Translations of the ESMO Patient Guides Now Available in the Croatian

noreply@esmo.org — Mon, 18 May 2026 08:05:00 +00:00

ESMO would like to thank the IGET for providing new translations of the Patient Guides in the Croatian language in collaboration with CORN

Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer

noreply@esmo.org — Mon, 18 May 2026 07:05:00 +00:00

Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study

EMA Recommends Extension of Indications for Nivolumab

noreply@esmo.org — Fri, 15 May 2026 07:05:00 +00:00

New indication concerns a combination with AVD chemotherapy regimen for the treatment of adults and adolescents with previously untreated Stage III or IV cHL

Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma

noreply@esmo.org — Thu, 14 May 2026 07:05:00 +00:00

Findings from the RMC-6236-001 study

FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer

noreply@esmo.org — Wed, 13 May 2026 07:05:00 +00:00

Evidence for efficacy is based on the results from the VERITAC-2 study

Aiming to support a robust regulatory ecosystem for driving cancer research in Europe, ESMO provides feedback to the public consultation on dataset descriptions under the European Health Data Space (EHDS)

noreply@esmo.org — Tue, 12 May 2026 08:05:00 +00:00

Facilitating the re-use of existing electronic health data for scientific research under the EHDS holds enormous potential to enable cross-border cancer research projects, drive therapeutic innovation in oncology, and ultimately support the development of promising new cancer therapies.

A Subgroup of Patients with a Very Poor Prognosis Diffuse Intrinsic Pontine Glioma Linked to TP53 Alterations

noreply@esmo.org — Tue, 12 May 2026 07:05:00 +00:00

Findings from the BIOMEDE study

A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality

noreply@esmo.org — Mon, 11 May 2026 07:05:00 +00:00

Findings from the NordiCC study

EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab

noreply@esmo.org — Fri, 08 May 2026 07:05:00 +00:00

It is a cancer medicine used to treat adult patients with multiple myeloma

Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC

noreply@esmo.org — Thu, 07 May 2026 07:05:00 +00:00

Updated efficacy and safety results from the TRUST-I study

National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors

noreply@esmo.org — Thu, 07 May 2026 07:05:00 +00:00

Hundreds of thousands of people diagnosed with cancer are still alive today but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis

EMA Recommends Extension of Indications for Dabrafenib and Trametinib

noreply@esmo.org — Wed, 06 May 2026 07:05:00 +00:00

New indications concern the treatment of adolescents from 12 years of age with melanoma and treatment of adult patients with differentiated thyroid cancer

Incorporating sTILs Into PREDICT Substantially Improves the Model’s Ability to Distinguish High- and Low-Risk Patients with TNBC

noreply@esmo.org — Tue, 05 May 2026 07:05:00 +00:00

Building the PREDICT_sTILs prognostication model

ESMO–ESTRO Joint Consensus Papers Address the Safety of Combining Radiotherapy with Targeted Cancer Therapies and Immunotherapy